As of May 2012 websites are required by law to gain your consent before applying cookies. We use cookies to improve your browsing experience. Parts of the website may not work as expected without them. By closing this message, you are consenting to our use of cookies. Close Learn more


Inflammatory Bowel Disease Package


> Download your free sample > Contact us to find out more



This comprehensive coverage provides up-to-date opinions and forecasts based on extensive secondary research backed by a survey of 211 high prescribing gastroenterologists and detailed discussions with KOLs.  Learn how the disease is currently treated, the unmet needs and how new market entrants (branded and generics/biosimilars) will affect the market in the future.

The Datamonitor Healthcare difference

What this package includes

Total number of physicians interviewed

US Japan France Germany Italy Spain UK
Gastroenterologists 30 31 30 30 30 30 30


Coverage summary

Reports included in package
  • Epidemiology
  • Marketed drugs profiles
  • Pipeline drugs profiles
  • Treatment (physician insights)
  • Patient-based drug forecasts
Countries evaluated US, Japan, France, Germany, Italy, Spain, UK
Patient-based drug forecast period 2012–21
Patient subpopulations forecasted
  • Ulcerative colitis
  • Crohn’s disease
  • Line of therapy
Drugs profiled
  • Apriso
  • Cimzia
  • Delzicol/Asacol HD
  • Humira
  • Lialda
  • Pentasa
  • Remicade
  • Simponi
  • Tysabri
  • Uceris
  • Stelara
  • Xeljanz
  • vedolizumab
  • vercirnon



Key Findings

The inflammatory bowel disease (IBD) market is to become increasingly crowded over the next decade with the anticipated launch of biosimilars from 2014, new products, and new formulations of existing generics. While the Crohn’s disease market is currently more lucrative than ulcerative colitis due to established biologics use, from 2016, ulcerative colitis-specific sales are forecast to overtake the Crohn’s disease market. Growth in the ulcerative colitis market is attributed to the higher prevalence growth rate of the indication relative to Crohn’s disease and five new product launches. Still, the view among physicians that surgery is a viable and curative option for ulcerative colitis patients poses a barrier for brand uptake.

> Download your free sample > Contact us to find out more


Datamonitor Healthcare is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726